(Reuters) – Sanofi announced on Monday that it had concluded an agreement in order to acquire the BluePrint Medicines biopharmaceutical company, based in the United States, in order to strengthen its portfolio in rare immunological diseases.

Under the terms of the acquisition, Sanofi will pay $ 129.00 per cash share, which represents a value in equity of around $ 9.1 billion (8.36 billion euros).

“The acquisition includes a medical activity specializing in rare immunological diseases, Ayvakit/Ayvakyt (Avapritinib), approved in the United States and the European Union, as well as a promising and early stage immunological pipeline,” said a Sanofi press release.

Ayvakit/Ayvakyt is the only drug approved for advanced and indolent systemic mastocytosis, a rare immunological disease, which is characterized by the accumulation and activation of aberrant mastocytes in bone marrow, skin, gastrointestinal tract and other organs.

Acquisition will also bring elenenestinib, a new generation drug for systemic mastocytosis, as well as BLU-808, a highly selective and powerful wild kit inhibitor, administered orally, which has the potential to treat a wide range of immunology diseases.

“Blueprint Medicines’ acquisition proposal represents a strategic bond in our rare diseases and immunology portfolios,” said Sanofi CEO, Paul Hudson.

“It completes the recent acquisitions of drugs in the early development phase which remain our main area of ​​interest”, he adds, adding that “Sanofi keeps a significant capacity for new acquisitions of assets”.

On the Paris Stock Exchange, the Sanofi action fell 0.7% to 86.96 euros in the first exchanges, against a decline of 0.39% for the CAC 40 at the same time.

(Redplained by Noemie Naudin, edited by Augustin Turpin and Blandine Hénault)

Copyright © 2025 Thomson Reuters